First Trust Advisors LP bought a new position in shares of AnaptysBio Inc (NASDAQ:ANAB) during the second quarter, HoldingsChannel.com reports. The firm bought 18,511 shares of the biotechnology company’s stock, valued at approximately $1,315,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Los Angeles Capital Management & Equity Research Inc. acquired a new position in AnaptysBio during the 2nd quarter worth $1,655,000. Creative Planning acquired a new position in AnaptysBio during the 2nd quarter worth $257,000. Xact Kapitalforvaltning AB acquired a new position in AnaptysBio during the 2nd quarter worth $242,000. Handelsbanken Fonder AB grew its holdings in AnaptysBio by 100.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 16,000 shares of the biotechnology company’s stock worth $1,137,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Brown Advisory Inc. grew its holdings in AnaptysBio by 54.7% during the 1st quarter. Brown Advisory Inc. now owns 100,614 shares of the biotechnology company’s stock worth $10,470,000 after acquiring an additional 35,584 shares in the last quarter.
NASDAQ ANAB opened at $86.11 on Friday. AnaptysBio Inc has a one year low of $30.84 and a one year high of $134.00. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $2.05 billion, a PE ratio of -56.65 and a beta of 2.81.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.70) by $0.13. equities analysts forecast that AnaptysBio Inc will post -2.61 EPS for the current year.
Several research analysts have weighed in on the stock. JMP Securities decreased their price objective on shares of AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a report on Wednesday, August 15th. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $93.00 price objective for the company in a report on Monday, August 13th. Royal Bank of Canada reissued a “hold” rating and set a $84.00 price objective on shares of AnaptysBio in a report on Wednesday, August 8th. Cantor Fitzgerald assumed coverage on shares of AnaptysBio in a report on Tuesday, September 4th. They set a “buy” rating and a $124.00 price objective for the company. Finally, ValuEngine raised shares of AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and a consensus price target of $126.30.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Article: Growth Stocks
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.